Researched and fact-checked in-house against primary literature and regulator records. Not reviewed by a named clinician — how we work.
Evidence-rated reference Updated August 2026
We sell nothing. No vendor sponsorship. Editorial policy
Pepteyes .com

The rankings

Three ways to order the same 89 compounds: by the evidence behind them, by the risk documented against them, and by what people are actually trying to achieve. Every position is calculated from the monographs, the arithmetic is published on each page, and no ranking on this site is a recommendation.

Ranking three

Ranked by what people want

The question people actually type, answered from the evidence rather than by whoever is selling the answer. 9 goals, each ranked by weight of human evidence.

Where risk runs furthest ahead of evidence

Subtract one score from the other and you get the number that matters most before anyone tries something: how far the documented downside outruns anything demonstrated about the upside.

  1. 1 BPC-157 +82
  2. 1 MOTS-c +82
  3. 3 Cartalax +80
  4. 3 IGF-1 LR3 +80
  5. 3 PE-22-28 +80

The full gap table sits on the risk ranking.